Metformin-associated lactic acidosis

American Journal of the Medical Sciences

Volumn 349, Issue 3, 2015, Pages 263-267

  Pasquel, Francisco J ^a   Klein, Robin ^a   Adigweme, Adaeze ^a   Hinedi, Ziad ^a   Coralli, Richard ^b   Pimentel, Juan L ^c   Umpierrez, Guillermo E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Atlanta Cardiology Group   (United States)

^c Northwest Nephrology Clinic   (United States)

Author keywords

Acidosis; Diabetes; Inpatient diabetes; Lactate; Metformin

Indexed keywords

ACTIVATED CARBON; DIURETIC AGENT; ISOPHANE INSULIN; LISINOPRIL; METFORMIN; PIG INSULIN; ANTIDIABETIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ASCITES; BLOOD CHEMISTRY; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONSERVATIVE TREATMENT; CRACKLE; DIABETIC PATIENT; DISTRESS SYNDROME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FAINTNESS; HEART FAILURE; HEMODIALYSIS; HEPATITIS C; HOSPITAL PATIENT; HUMAN; INSULIN TREATMENT; JAUNDICE; KIDNEY FAILURE; LABORATORY TEST; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LUNG AUSCULTATION; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATIENT MONITORING; PATIENT SELECTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; THORAX PAIN; THORAX RADIOGRAPHY; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2;

ACIDOSIS, LACTIC; AGED; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 84925622469     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182a562b7     Document Type: Article

References (53)

1. Diamant M. Choosing a blood-glucose-lowering agent after metformin. Lancet 2012;379:2220-1
2. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
3. Nyenwe EA, Jerkins TW, Umpierrez GE, et al. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011;60:1-23
4. Maida A, Lamont BJ, Cao X, et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011;54:339-49
5. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011;54:219-22
6. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
7. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
8. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;CD002967
9. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004;27:1791-3
10. Stades AM, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence?. A review of case reports. J Intern Med 2004;255:179-87
11. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602
12. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point?. Diabetologia 2005;48:2454-9
13. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63
14. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6
15. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993;44:589-91
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577-96
17. Eurich DT, Tsuyuki RT, Majumdar SR, et al. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 2009;10:12
18. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51
19. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90
20. Evans JM, Doney AS, AlZadjali MA, et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010;106:1006-10
21. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-8
22. Kosmalski M, Drozdowska A, Sliwinska A, et al. Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients. Adv Med Sci 2012;57:65-70
23. Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434-7
24. Holstein A, Nahrwold D, Hinze S, et al. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6
25. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8
26. Peters N, Jay N, Barraud D, et al. Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008;12:R149
27. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011;36: 376-82
28. Biradar V, Moran JL, Peake SL, et al. Metformin-associated lactic acidosis (MALA): clinical profile and outcomes in patients admitted to the intensive care unit. Crit Care Resusc 2010;12:191-5
29. Nyirenda MJ, Sandeep T, Grant I, et al. Severe acidosis in patients taking metformin-rapid reversal and survival despite high APACHE score. Diabet Med 2006;23:432-5
30. Personne M. Alarming increase of the number of metformin intoxications. Ten times doubled number of inquiries to the Swedish Poison Information Center since 2000 [in Swedish]. Lakartidningen 2009;106: 994
31. Cryer DR, Nicholas SP, Henry DH, et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28:539-43
32. Vecchio S, Protti A. Metformin-induced lactic acidosis: no one left behind. Crit Care 2011;15:107
33. Waters AK, Morgan DB, Wales JK. Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas. Diabetologia 1978;14:95-8
34. Czyzyk A, Lao B, Bartosiewicz W, et al. The effect of short-term administration of antidiabetic biguanide derivatives on the blood lactate levels in healthy subjects. Diabetologia 1978;14:89-94
35. Schaffalitzky de Muckadell OB, Mortensen H, Lyngsoe J. Metabolic effects of glucocorticoid and ethanol administration in phenformin- and metformin-treated obese diabetics. Acta Med Scand 1979;206:269-73
36. Irsigler K, Kritz H, Regal H, et al. The risk of lacticate acidosis: a comparison of the 3 biguanides in treatment of diabetics (authors' transl) [in German]. Wien Klin Wochenschr 1978;90:332-7
37. Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract 2000; 6:442-6
38. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008;51:1552-3
39. Hong Y, Rohatagi S, Habtemariam B, et al. Population exposureresponse modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48:696-707
40. Keller G, Cour M, Hernu R, et al. Management of metformin-associated lactic acidosis by continuous renal replacement therapy. PLoS One 2011; 6:e23200
41. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607-14
42. Levy B, Perez P, Perny J.Where does the lactate come from?. A rare cause of reversible inhibition of mitochondrial respiration. Crit Care 2010;14:136
43. Leverve XM. Mitochondrial function and substrate availability. Crit Care Med 2007;35(suppl 9):S454-60
44. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003;13:581-4
45. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
46. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
47. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother 2012;13:1797-805
48. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89:837-44
49. Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab 2003;5:93-8
50. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanidetreated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87
51. Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol (Oxf) 2011;74:191-6
52. Friesecke S, Abel P, Roser M, et al. Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care 2010;14:R226
53. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18:779-84